ABL1 and cerebrovascular disorder: Cardiovascular events, including ischemic heart disease, cerebrovascular disease, and peripheral artery disease, are major concerns in patients with CML, particularly in those under treatment with second- and third-generation Bcr-ABL TKIs nilotinib and ponatinib, respectively (14).